Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Review Article

Natriuretic Peptides in Gastrointestinal Cancer: Biomarkers and Potential Therapeutic Targets

In Press, (this is not the final "Version of Record"). Available online 06 November, 2023
Author(s): Sajjad Sadeghpour, Mahla Velayati, Nima Zafari, Samaneh Mollazadeh, Shima Mehrabadi, Mina Maftooh, Seyed Mahdi Hassanian, Majid Ghayour-Mobarhan, Gordon A. Ferns, Mohammad Ali Kiani, Majid Khazaei and Amir Avan*
Published on: 06 November, 2023

DOI: 10.2174/0125899775237721231024092023

Price: $95

Abstract

Gastrointestinal (GI) cancers are an important health problem globally. Natriuretic peptides are hormones that have a crucial role in human physiology. There are a variety of treatments for GI cancer, but conventional therapies have side effects and low efficacy. Studies have demonstrated that natriuretic peptides are therapeutic in different cancer types. Natriuretic peptides are best known for their involvement in regulating blood pressure and blood volume. The anti-tumor effect exerted by natriuretic peptides is via their inhibitory effects on DNA synthesis and by their effects on apoptosis. The anti-proliferative role of natriuretic peptides has been shown in human breast cancer, prostate, colon, pancreatic, lung, ovarian, and other tumors. The roles of natriuretic peptides in these cancers are diverse and not well understood. Therefore, we have reviewed the recent literature on natriuretic peptides in GI cancers as a common malignancy in adults to assess the pathways that NPs are involved in the progression of GI cancers and its effect on the prevention or treatment of GI cancers.

Keywords: natriuretic peptides, gastrointestinal cancer, biomarker, therapeutic targets


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy